3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow MG4101: new trials by email Literature Review of MG4101 trials Research Report on MG4101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MG4101 for Refractory or Relapsed AML MG4101 - Acute Myeloid Leukemia | Phase 2 | Completed | Seoul National University Hospital | 11 | 2017-11-01 | 2023-04-18 |
| A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma MG4101 - Hepatocellular Carcinoma | Phase 2 | Completed | GC Cell Corporation | 78 | 2016-11-28 | 2019-09-26 |
| to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) MG4101 - Hepatocellular Carcinoma | Phase 2 | Completed | Samsung Medical Center | 5 | 2014-08-01 | 2015-12-03 |
Carcinoma, Hepatocellular (2) · Leukemia, Myeloid, Acute (1)
GC Cell Corporation (1) · Samsung Medical Center (1) · Seoul National University Hospital (1)
South Korea (3)
Jae-Won Joh, MD., PhD (1) · Jung Hwan Yoon, M.D., Ph.D. (1) · Youngil Koh, MD (1)